home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

41.24 +0.07 (+0.17%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

21 22 Next >

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

May 07, 2024

From Exelixis, Inc.

Via Business Wire

The Analyst Verdict: Exelixis In The Eyes Of 5 Experts ↗

May 01, 2024

Via Benzinga

Exelixis (EXEL) Q1 2024 Earnings Call Transcript ↗

May 01, 2024

EXEL earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

EXEL Stock Earnings: Exelixis Misses EPS, Misses Revenue for Q1 2024 ↗

April 30, 2024

EXEL stock results show that Exelixis missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update

April 30, 2024

From Exelixis, Inc.

Via Business Wire

Technical Signals Point to a Possible Breakout for EXELIXIS INC. ↗

April 24, 2024

EXELIXIS INC (NASDAQ:EXEL) Reveals Intriguing Technical Aspects. Here's What You Need to Know.

Via Chartmill

What Analysts Are Saying About Exelixis Stock ↗

April 10, 2024

Via Benzinga

2 Stocks Under $30 to Buy and Hold ↗

February 19, 2024

You don't need to be a millionaire to get started. Investing on a budget can work, too.

Via The Motley Fool

The Top 3 Biotech Stocks to Buy in April 2024 ↗

April 27, 2024

Learn about the top three biotech stocks to take advantage of these companies' promising futures and pharmaceutical advances.

Via InvestorPlace

NASDAQ:EXEL is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

April 24, 2024

EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.

Via Chartmill

Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024

April 16, 2024

From Exelixis, Inc.

Via Business Wire

NASDAQ:EXEL is an undervalued gem with solid fundamentals. ↗

March 29, 2024

For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.

Via Chartmill

3 Biotech Stocks to Buy on the Dip: March 2024 ↗

March 27, 2024

Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.

Via InvestorPlace

Recap: Exelixis Q4 Earnings ↗

February 06, 2024

Via Benzinga

4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market ↗

March 23, 2024

Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.

Via The Motley Fool

Topics Stocks

5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024 ↗

March 09, 2024

Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the...

Via Talk Markets

2 Biotech Stocks to Buy Hand Over Fist in March ↗

March 08, 2024

These stocks are worth buying in most months of the year.

Via The Motley Fool

3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success ↗

March 06, 2024

With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector.

Via InvestorPlace

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. ↗

March 05, 2024

EXELIXIS INC (NASDAQ:EXEL) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market ↗

March 02, 2024

The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.

Via The Motley Fool

Topics Stocks

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March

February 27, 2024

From Exelixis, Inc.

Via Business Wire

Around $4M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying ↗

February 23, 2024

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

Via Benzinga

The 3 Best Biotech Stocks to Buy in February 2024 ↗

February 13, 2024

The best biotech stocks to buy offer consistent growth opportunities and resist the influence of singular drug successes.

Via InvestorPlace

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. ↗

February 13, 2024

For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.

Via Chartmill

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

February 14, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

4 Appealing Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

February 10, 2024

The growth-driven Nasdaq Composite hasn't put the 2022 bear market entirely in the rearview mirror, which means opportunistic investors can still find bargains.

Via The Motley Fool

Topics Stocks

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

February 14, 2024

From FN Media Group LLC

Via GlobeNewswire

3 Attractive Medical Stocks To Buy After Earnings ↗

February 08, 2024

Quite a few top-rated stocks have highlighted this week’s earnings lineup with now appearing to be an ideal time to buy. Following their favorable quarterly results, here are 3 intriguing healthcare...

Via Talk Markets

Exelixis (EXEL) Q4 2023 Earnings Call Transcript ↗

February 06, 2024

EXEL earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

February 06, 2024

From Exelixis, Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com